A twice-yearly injectable drug, lenacapavir, hailed as a breakthrough in HIV prevention, could be available in Canada by ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.

Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

The US has approved lenacapavir for HIV prevention. However, experts worry that cuts to the health budget will "squander" the drug's chance of reducing infections.

The Makerere University–Johns Hopkins University Research Collaboration has announced ongoing studies aimed at extending the ...